Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel To Consider Calcitonin Drugs’ Need For Fracture Data In Light Of Potential Cancer Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

The Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees will consider whether new calcitonin drugs for osteoporosis should show reduction in risk for fractures, a clinical benefit required of other osteoporosis medications.

You may also be interested in...



FDA Keeps Calcitonin Products On The Market But Narrows Osteoporosis Claim

Saying its review found “no conclusive evidence of a causal relationship” between the products and cancer, agency is allowing continued marketing of Miacalcin and Fortical nasal sprays but limiting use to only those post-menopausal women for whom alternative treatments are not suitable.

Tarsa Raises $28 Million Series B to Support Regulatory Filings of Oral Calcitonin

Privately held firm believes oral calcitonin will enjoy several advantages over other osteoporosis therapies – ease of use compared to calcitonin nasal spray and safety compared to bisphosphonates.

With Its Hypertension Franchise in Crisis, Novartis Restructures

Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.

Topics

Related Companies

UsernamePublicRestriction

Register

PS075370

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel